CLVS - Clovis reports early data for tumor candidate to indicate partial response

Announcing initial Phase 1 data for its radionuclide therapy FAP-2286 in solid tumors, Clovis Oncology (NASDAQ:CLVS) said on Tuesday that one patient out of nine treated with the experimental therapy developed a confirmed partial response. The Phase 1 portion of the Phase 1/2 LuMIERE study is designed to identify the recommended Phase 2 dose and the schedule for FAP-2286 labeled with lutetium-177. A total of nine patients received 177Lu-FAP-2286 up to 5.5 GBq/dose in the first two dose cohorts. One heavily pre-treated patient in the 3.7 GBq dose cohort after completing six administrations of the therapy indicated a confirmed RECIST partial response. There were no dose-limiting toxicities in safety evaluable patients in the 3.7 or 5.55 GBq cohorts (n=3 in each cohort). Clovis (CLVS) is currently enrolling patients for the third dose cohort (7.4 GBq). The company plans to start the Phase 2 portion of the study during the fourth

For further details see:

Clovis reports early data for tumor candidate to indicate partial response